Agios Pharmaceuticals (AGIO) Expected to Post Earnings on Thursday

Agios Pharmaceuticals (NASDAQ:AGIO) is expected to announce its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect Agios Pharmaceuticals to post earnings of ($1.24) per share and revenue of $51.65 million for the quarter. Individuals can find conference call details on the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Thursday, November 5, 2026 at 8:00 AM ET.

Agios Pharmaceuticals Stock Performance

Shares of NASDAQ:AGIO opened at $31.20 on Wednesday. The stock has a 50-day simple moving average of $33.53 and a 200-day simple moving average of $31.72. The stock has a market capitalization of $1.86 billion, a P/E ratio of -4.45 and a beta of 0.66. Agios Pharmaceuticals has a 1 year low of $22.24 and a 1 year high of $46.00.

Analysts Set New Price Targets

Several research firms have issued reports on AGIO. Royal Bank Of Canada boosted their price objective on shares of Agios Pharmaceuticals from $28.00 to $32.00 and gave the stock a “sector perform” rating in a research note on Tuesday, July 7th. Weiss Ratings reissued a “sell (d)” rating on shares of Agios Pharmaceuticals in a research report on Monday, September 21st. Truist Financial cut their target price on shares of Agios Pharmaceuticals from $39.00 to $37.00 and set a “buy” rating on the stock in a research note on Wednesday, October 7th. Citigroup lifted their target price on shares of Agios Pharmaceuticals from $46.00 to $52.00 and gave the company a “buy” rating in a report on Friday, July 31st. Finally, JPMorgan Chase & Co. upped their price target on shares of Agios Pharmaceuticals from $31.00 to $34.00 and gave the stock a “neutral” rating in a research report on Friday, August 7th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $41.50.

Insider Activity at Agios Pharmaceuticals

In related news, insider Sarah Gheuens sold 7,866 shares of the business’s stock in a transaction that occurred on Monday, October 26th. The stock was sold at an average price of $37.69, for a total transaction of $296,469.54. Following the transaction, the insider directly owned 54,645 shares of the company’s stock, valued at approximately $2,059,570.05. The trade was a 12.58% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 9,855 shares of company stock worth $371,112. Company insiders own 5.40% of the company’s stock.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc is a biopharmaceutical company focused on discovering and developing medicines for rare diseases involving cellular metabolism. The company’s research is centered on metabolic pathways that influence red blood cell production and function, with the goal of addressing conditions that have limited treatment options.

Agios’ principal commercial product is Pyrukynd (mitapivat), an oral activator of pyruvate kinase. Pyrukynd is approved in the United States and other markets for the treatment of hemolytic anemia in adults with pyruvate kinase deficiency, a rare inherited blood disorder.